MDM2 and acute myeloid leukemia: p53 transcriptional activity is physiologically regulated by the E3 ubiquitin-protein ligase MDM2; therefore, MDM2 inhibitors are currently being tested in AML [133], suggesting idasanutlin to be the most selective and potent drug.